Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in ... Wall Street Journal Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with previously untreated ... |
